RxDoctor Payments Data

Murray Friedberg, MD

Ophthalmology · Bradenton, FLNPI 1609874874

Payments from drug & device makers

$2,158in general payments, 2019–2025

Across 71 payments — averaging $30.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$885
  • AbbVie$558
  • Harrow Eye, LLC$152
  • Bausch & Lomb Americas Inc.$151
  • Ocular Therapeutix, Inc.$98
  • Sun Pharmaceutical Industries Inc.$64
  • plus $251 from 7 others

What the payments were for

  • Food & beverage$2,158100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,158 in reported general payments places this provider in the 50th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$592,862
Medicare patients
1,984
Services billed
4,966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine123$131,987
ProlensaBromfenac Sodium145$49,700
LumiganBimatoprost118$47,200
BesivanceBesifloxacin Hcl191$41,900
XiidraLifitegrast13$23,333
Cyclosporine37$20,216
Prednisolone Acetate448$19,430
Lotemax SmLoteprednol Etabonate41$10,232
IlevroNepafenac25$9,177
Loteprednol Etabonate34$7,269
Bromfenac Sodium33$6,243
SimbrinzaBrinzolamide/Brimonidine Tart11$5,858
Gatifloxacin120$5,497
Latanoprost588$5,125
Fluorometholone64$4,772

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$558$183,634256 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Besivance, Lotemax Sm, Loteprednol Etabonate$30$109,102411 claims
Bausch & Lomb Americas Inc.Xiidra$151$23,33313 claims
NovartisIlevro$43$9,17725 claims
AlconSimbrinza$885$5,85811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →